Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Adv Drug Deliv Rev. 2021 Sep 13;178:113971. doi: 10.1016/j.addr.2021.113971

Fig. 5.

Fig. 5.

Classes of biologics delivered by local biomaterial-based delivery strategies. (A) Antibody-based treatments are used to interfere with signaling of inflammatory cytokines such as IL-6 and TNFα. (B) Chemokines, such as CCL22, CXCL12 and CCL1, can be delivered to generate a chemotactic gradient capable of recruiting regulatory T cells to a specific site of interest. (C) Various cytokines can be delivered to drive differentiation of immature or tolerogenic dendritic cell subtypes (colony-stimulating factors), increase regulatory immune responses (interleukins), induce apoptosis of autoreactive immune cells (TNF family) or generate regulatory T cells (TGFβ1).